PMID- 32219096
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2296-861X (Print)
IS  - 2296-861X (Electronic)
IS  - 2296-861X (Linking)
VI  - 7
DP  - 2020
TI  - Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative 
      Approach for Managing Breast Cancer.
PG  - 21
LID - 10.3389/fnut.2020.00021 [doi]
LID - 21
AB  - Breast cancer remains as a significant cause of morbidity and mortality in women. 
      Ultrastructural and biochemical evidence from breast biopsy tissue and cancer 
      cells shows mitochondrial abnormalities that are incompatible with energy 
      production through oxidative phosphorylation (OxPhos). Consequently, breast 
      cancer, like most cancers, will become more reliant on substrate level 
      phosphorylation (fermentation) than on oxidative phosphorylation (OxPhos) for 
      growth consistent with the mitochondrial metabolic theory of cancer. Glucose and 
      glutamine are the prime fermentable fuels that underlie therapy resistance and 
      drive breast cancer growth through substrate level phosphorylation (SLP) in both 
      the cytoplasm (Warburg effect) and the mitochondria (Q-effect), respectively. 
      Emerging evidence indicates that ketogenic metabolic therapy (KMT) can reduce 
      glucose availability to tumor cells while simultaneously elevating ketone bodies, 
      a non-fermentable metabolic fuel. It is suggested that KMT would be most 
      effective when used together with glutamine targeting. Information is reviewed 
      for suggesting how KMT could reduce systemic inflammation and target tumor cells 
      without causing damage to normal cells. Implementation of KMT in the clinic could 
      improve progression free and overall survival for patients with breast cancer.
CI  - Copyright (c) 2020 Seyfried, Mukherjee, Iyikesici, Slocum, Kalamian, Spinosa and 
      Chinopoulos.
FAU - Seyfried, Thomas N
AU  - Seyfried TN
AD  - Biology Department, Boston College, Chestnut Hill, MA, United States.
FAU - Mukherjee, Purna
AU  - Mukherjee P
AD  - Biology Department, Boston College, Chestnut Hill, MA, United States.
FAU - Iyikesici, Mehmet S
AU  - Iyikesici MS
AD  - Medical Oncology, Kemerburgaz University Bahcelievler Medical Park Hospital, 
      Istanbul, Turkey.
FAU - Slocum, Abdul
AU  - Slocum A
AD  - Medical Oncology, Chemo Thermia Oncology Center, Istanbul, Turkey.
FAU - Kalamian, Miriam
AU  - Kalamian M
AD  - Dietary Therapies LLc, Hamilton, MT, United States.
FAU - Spinosa, Jean-Pierre
AU  - Spinosa JP
AD  - Gynecologic and Breast Oncology, Clinique Cecil, Lausanne, Switzerland.
FAU - Chinopoulos, Christos
AU  - Chinopoulos C
AD  - Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200311
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC7078107
OTO - NOTNLM
OT  - fermentation
OT  - glutaminolysis
OT  - glycolysis
OT  - inflammation
OT  - metastasis
OT  - non-toxic
OT  - survival
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
PMCR- 2020/01/01
CRDT- 2020/03/29 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fnut.2020.00021 [doi]
PST - epublish
SO  - Front Nutr. 2020 Mar 11;7:21. doi: 10.3389/fnut.2020.00021. eCollection 2020.